FDA Grants Orphan Drug Designation for TLX102
Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple myeloma.
First Patient Dosed in Renal Cancer Imaging Study in Japan
Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in Japan
Telix H1 2020 Results and Company Update Conference Call
Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s operations.
Drug Master File for Glioblastoma Therapy Product Filed with FDA
Telix announces it has submitted a Drug Master File to the FDA for TLX101 (4-[131I]Iodol-phenylalanine injection)
Activities Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales update
Telix Pharmaceuticals Receives $11.4M R&D Tax Refund
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product
Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT trial
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product TLX250-CDx
Recommencement of ZIRCON Phase III Trial Recruitment in EU
Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in Europe.